{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:15:34Z","timestamp":1783350934666,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To explore the efficacy and safety of rituximab (RTX) in the treatment of autoimmune nephropathy manifested as refractory nephrotic syndrome (RNS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-center prospective cohort study was conducted on RNS patients treated with RTX between March 2017 and December 2019. The subjects were divided into the primary nephropathy (PN) group and the secondary nephropathy (SN) group. Based on the estimated glomerular filtration rate (eGFR) before RTX treatment, the SN group was then divided into the SN-1 group (eGFR\u2009\u2265\u200930\u00a0ml\/min) and the SN-2 group (eGFR\u2009&lt;\u200930\u00a0ml\/min). Biochemical parameters and clinical data were recorded during follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-four patients were followed up for at least 6\u00a0months. The overall remission rates were 65%, 66.7%, 27.3% in the PN, SN-1, and SN-2 groups, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.022). Kaplan\u2013Meier analysis showed a significant difference of the renal survival among the three subgroups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariate Cox regression analysis showed that eGFR value before treatment was an independent predictor (HR 0.919, 95%CI 0.863\u20130.979) for renal survival. In terms of adverse events, infection accounted for 56.6%. The incidence of severe infection was 10%, 25% and 50% in PN group, SN-1 group and SN-2 group, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RTX may be a promising option in RNS patients with eGFR\u2009\u2265\u200930\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>. However, it has little effect on prognosis in patients with secondary RNS with eGFR\u2009&lt;\u200930\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>, but with a high risk of severe infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-021-02860-4","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:06:45Z","timestamp":1619528805000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome"],"prefix":"10.1007","volume":"54","author":[{"given":"Jing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"4","key":"2860_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"1","key":"2860_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L et al (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28(1):348\u2013358","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2860_CR3","first-page":"311","volume":"17","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N et al (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 17(3):311\u2013320","journal-title":"N Engl J Med"},{"issue":"9","key":"2860_CR4","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"J van den Brand","year":"2017","unstructured":"van den Brand J, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B et al (2017) Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 28(9):2729\u20132737","journal-title":"J Am Soc Nephrol"},{"issue":"9950","key":"2860_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950):1273\u20131281","journal-title":"Lancet"},{"issue":"8","key":"2860_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T et al (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757\u2013764","journal-title":"JAMA Pediatr"},{"issue":"3","key":"2860_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R et al (2013) Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83(3):511\u2013516","journal-title":"Kidney Int"},{"issue":"1","key":"2860_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10157-015-1139-6","volume":"20","author":"Y Miyabe","year":"2016","unstructured":"Miyabe Y, Takei T, Iwabuchi Y, Moriyama T, Nitta K (2016) Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Clin Exp Nephrol 20(1):103\u2013110","journal-title":"Clin Exp Nephrol"},{"issue":"55","key":"2860_CR9","doi-asserted-by":"publisher","first-page":"93438","DOI":"10.18632\/oncotarget.21833","volume":"8","author":"H Ren","year":"2017","unstructured":"Ren H, Lin L, Shen P, Li X, Xie J, Pan X et al (2017) Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis. Oncotarget 8(55):93438\u201393443","journal-title":"Oncotarget"},{"issue":"5","key":"2860_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A et al (2013) Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transpl 28(5):1225\u20131232","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"2860_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215\u20131226","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2860_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1191\/0961203303lu453cr","volume":"12","author":"GP Fra","year":"2003","unstructured":"Fra GP, Avanzi GC, Bartoli E (2003) Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 12(10):783\u2013787","journal-title":"Lupus"},{"issue":"2","key":"2860_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.ajkd.2008.03.036","volume":"52","author":"L Camous","year":"2008","unstructured":"Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noel LH et al (2008) Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 52(2):346\u2013352","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2860_CR14","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8(3):R83","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2860_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/0961203313483376","volume":"22","author":"RJ Davies","year":"2013","unstructured":"Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R et al (2013) Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22(6):574\u2013582","journal-title":"Lupus"},{"issue":"3","key":"2860_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2215\/CJN.04030808","volume":"4","author":"C Melander","year":"2009","unstructured":"Melander C, Sallee M, Trolliet P, Candon S, Belenfant X, Daugas E et al (2009) Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4(3):579\u2013587","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2860_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211\u2013220","journal-title":"N Engl J Med"},{"issue":"3","key":"2860_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221\u2013232","journal-title":"N Engl J Med"},{"key":"2860_CR19","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1\u2013266"},{"key":"2860_CR20","doi-asserted-by":"publisher","first-page":"973609","DOI":"10.1155\/2014\/973609","volume":"2014","author":"P Pateinakis","year":"2014","unstructured":"Pateinakis P, Pyrpasopoulou A (2014) CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? Biomed Res Int 2014:973609","journal-title":"Biomed Res Int"},{"issue":"9","key":"2860_CR21","first-page":"1558","volume":"33","author":"X Wang","year":"2018","unstructured":"Wang X, Cui Z, Zhang YM, Qu Z, Wang F, Meng LQ et al (2018) Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrol Dial Transplant 33(9):1558\u20131563","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2860_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2215\/CJN.00570109","volume":"4","author":"G Fernandez-Fresnedo","year":"2009","unstructured":"Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N et al (2009) Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4(8):1317\u20131323","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2860_CR23","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R et al (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26(4):976\u2013985","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2860_CR24","first-page":"461","volume":"10","author":"C Trivin","year":"2017","unstructured":"Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C et al (2017) Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J 10(4):461\u2013469","journal-title":"Clin Kidney J"},{"issue":"10","key":"2860_CR25","first-page":"1691","volume":"32","author":"G Moroni","year":"2017","unstructured":"Moroni G, Depetri F, Del VL, Gallelli B, Raffiotta F, Giglio E et al (2017) Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transpl 32(10):1691\u20131696","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"2860_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/RHU.0b013e31829d5017","volume":"19","author":"CT Weng","year":"2013","unstructured":"Weng CT, Liu MF, Weng MY, Lee NY, Wang MC, Lin WC et al (2013) Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol 19(5):252\u2013258","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"2860_CR27","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center. Arthritis Rheum 64(11):3770\u20133778","journal-title":"Arthritis Rheum"},{"issue":"19","key":"2860_CR28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02860-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02860-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02860-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:38:27Z","timestamp":1641382707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02860-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2860"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02860-4","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Peking University International Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}